2023 World Conference on Lung Cancer (Posters)-EP06.05. Validation of the IASLC Grading System of Invasive Adenocarcinoma of the Lung in Small Volume Center

EP06.05. Validation of the IASLC Grading System of Invasive Adenocarcinoma of the Lung in Small Volume Center - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to validate the International Association for the Study of Lung Cancer (IASLC) histologic grading system for invasive lung adenocarcinoma in a small volume center. The study included 108 patients who underwent pulmonary resection for stage I to IIIA adenocarcinoma. The patients were divided into three groups based on the architectural system and the IASLC grading system. The architectural system categorized tumors into low, intermediate, and high groups based on the predominant tumor pattern, while the IASLC system added a high-grade subtype component. The study evaluated the prognostic implication of the IASLC system compared to the architectural system using recurrence-free survival (RFS) as the endpoint. <br /><br />The results showed that the area under the curve (AUC) for the IASLC system was 0.760 for RFS, while the AUC for the architectural system was 0.720 for RFS. This indicates that the IASLC grading system had a slightly better prediction of RFS compared to the architectural system. The study concluded that the IASLC grading system has similar prognostic significance and could be a promising tool for physicians in making postoperative decisions for patients with invasive lung adenocarcinoma. <br /><br />Keywords for this study include lung cancer, adenocarcinoma, and grading system. The findings of this study contribute to the field of pathology and biomarkers and add to the understanding of the IASLC grading system for lung adenocarcinoma.

Asset Subtitle

Kisung Park

Meta Tag

Speaker Kisung Park

Topic Pathology & Biomarkers

Keywords

lung cancer

adenocarcinoma

grading system

IASLC

histologic grading

invasive lung adenocarcinoma

pulmonary resection

architectural system

recurrence-free survival

prognostic implication